Skip to content
OpenCapital
Get started

OnKure Therapeutics, Inc. OKUR Q2 2025 earnings

Reported August 12, 2025 · Before market open

EPS-$1.14Beat by $0.09
EPS estimate-$1.23

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$166.7K
EPS estimate-$0.58

Financials

Q2 2025

Income statement

See full
Operating income-$16.3M-13.8%
Net income-$15.4M-8.8%
EPS (diluted)-$1.14+97.5%

Balance sheet

See full
Cash & equivalents$83.4M+132%
Total debt$823.0K0.0%
Total equity$78.2M+163%
Total assets$86.1M+9.3%

Cash flow

See full
Operating cash flow-$13.3M-105%
CapEx$13.0K+30.0%
Free cash flow-$13.3M-105%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$108.91M—
Enterprise value$26.35M—

Returns & leverage

See full
Debt / equity0×—
Current ratio11.1×-46.7×

Versus estimates

Diluted EPS

Q1 2026-$1.11Miss by $0.30Q4 2025-$0.99Beat by $0.16Q3 2025-$1.09Beat by $0.11
Q2 2025-$1.14Beat by $0.09
Q1 2025-$1.19Beat by $0.13Q4 2024-$1.37Miss by $0.51

Ask the moment OnKure Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did OnKure Therapeutics, Inc. report Q2 2025 earnings?
OnKure Therapeutics, Inc. (OKUR) reported Q2 2025 earnings on August 12, 2025 before market open.
What were OnKure Therapeutics, Inc.'s Q2 2025 revenue and EPS?
OnKure Therapeutics, Inc. reported eps of $-1.14 for Q2 2025.
Did OnKure Therapeutics, Inc. beat estimates in Q2 2025?
EPS beat the consensus estimate of $-1.23 by $0.09.
How did OnKure Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 28.8% from $-1.60.
Where can I find OnKure Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001193125-25-178981) directly on SEC EDGAR. The filing index links above go to sec.gov.